The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
about
Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trialsPersistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsCognition enhancers for the treatment of dementia.A Stability-Indicating HPLC Method for the Determination of Memantine Hydrochloride in Dosage Forms through Derivatization with 1-Fluoro-2,4-dinitrobenzeneMild cognitive impairment and mild dementia: a clinical perspective.Acetylcholinesterase inhibitors: pharmacology and toxicology.Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs.Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.The contribution of diseases to the male-female disability-survival paradox in the very old: results from the Newcastle 85+ study.Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculatureThe Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in TaiwanAge-related neurodegenerative disease research needs aging modelsMemantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review.Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.Cross-View Neuroimage Pattern Analysis in Alzheimer's Disease Staging.Nicotinic receptors in neurodegeneration.A genetically immortalized human stem cell line: a promising new tool for Alzheimer's disease therapy.Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease.Prevalence and management of dementia in primary care practices with electronic medical records: a report from the Canadian Primary Care Sentinel Surveillance Network.Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect.Disease-modifying drugs in Alzheimer's disease.Predicting the progression of Alzheimer's disease dementia: A multidomain health policy model.Predictors of care home and hospital admissions and their costs for older people with Alzheimer's disease: findings from a large London case register.Drug prescription appropriateness in the elderly: an Italian study.Redesigning systems of care for older adults with Alzheimer's disease.The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis.Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale.The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity.Efficacy of memantine hydrochloride once-daily in Alzheimer's disease.Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies.Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK.New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease.Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease.Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations.Synthesis and Biological Evaluation of Benzochromenopyrimidinones as Cholinesterase Inhibitors and Potent Antioxidant, Non-Hepatotoxic Agents for Alzheimer's Disease.New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition.Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
P2860
Q26851862-00D517DD-5BE2-445F-80DF-366138FD0EFCQ26997299-AF40FC1A-479B-4747-84FC-10E1D8C9FDE1Q30872331-13DE7A46-6D55-4399-8C38-F74153F5D229Q33784405-67EFFEDB-67F3-409A-9F09-E6C529A6F242Q34289991-990A7C8F-7C41-4C4C-84E4-5D4FCFF4BFA6Q34381860-D4C6036D-8DEE-4830-A557-B03F1687F58BQ34487826-E4229309-DD5A-4825-97F2-C6D4E147D0BEQ34543773-09B5F424-0974-42DF-A75F-95C29D6B6E07Q34629649-56F331AF-51AC-438C-9AF4-C5B53384D2A7Q35091510-2DB8B220-6B30-463D-9BFC-46F934AE48DDQ35127516-1556DD00-3CF4-4445-8D6C-AE89B67F15ADQ35670849-ABFBB07C-F00B-4BA3-A1E7-64EE211689ADQ36018230-3EC3E60F-2A02-4EF3-887B-894B3463AEC0Q36045044-E1E1A8A8-106E-43AA-8A68-B13AB0110522Q36288900-601AB131-4F14-4BFA-BC4F-FE86B89EC8CFQ36606287-B69389E6-E138-494F-9D3B-A3A27A4938E4Q36828916-7D6EF831-071E-4FC7-AEB3-AEA184C02732Q36847399-BCC67D88-189E-4098-A441-F306AA5ABB56Q37004843-0FBA6D6A-8FA7-49F8-AD6E-A6C6E6DC201AQ37066780-F3740E72-E6B2-4134-968C-BC04EDE850D0Q37098664-D8D365B7-ECDD-4964-9A79-1F7C049A5110Q37390739-46A365D8-441B-4AF5-A302-8D975B804D68Q37407212-02741DB5-FBE2-4A93-889F-964106639968Q37454280-8F4CCFFB-B53A-43AF-9B1A-1541391B6FF8Q37645846-A6F02B17-BBC8-4676-83E8-3C70B2B48166Q37681046-CCB3B5A8-EC07-4267-A044-38F46E1BC57CQ37704441-8610F13A-5196-4D87-843A-C152C61081ABQ37709832-34802010-463B-4597-B80C-742AE72685F3Q38167693-9D4863B2-12E3-4803-A504-9200E9212544Q38217301-3A564B46-3EA5-4CE3-8D91-B5966658681BQ38236190-7676FEF9-947C-4260-BC30-4B088628375EQ38260217-B3EF609F-3EF5-41BE-AA93-A470BA50B6BCQ38592069-27EEEFB4-E075-415F-9525-8F2D9E385533Q38671198-E7C5E590-DD16-4ECF-A64F-9EFE5C3272F8Q38686081-B1041B2D-3415-41AF-BA1F-F21AAC92E251Q38743343-92CB650B-C88F-457D-9CE8-9239E434DB36Q38749068-E18BAF1D-0D3B-4F43-AC18-3CDDA3AC6E0DQ38770442-C2A7F369-9F7F-47D4-85C7-CBA495BB736AQ38842928-4FC5E766-F92E-4DD9-8773-3A38705DC6EEQ38906350-8E5363E8-F69D-4C52-88BB-A9B380BAE720
P2860
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The effectiveness and cost-eff ...... tic review and economic model.
@ast
The effectiveness and cost-eff ...... tic review and economic model.
@en
The effectiveness and cost-eff ...... tic review and economic model.
@nl
type
label
The effectiveness and cost-eff ...... tic review and economic model.
@ast
The effectiveness and cost-eff ...... tic review and economic model.
@en
The effectiveness and cost-eff ...... tic review and economic model.
@nl
prefLabel
The effectiveness and cost-eff ...... tic review and economic model.
@ast
The effectiveness and cost-eff ...... tic review and economic model.
@en
The effectiveness and cost-eff ...... tic review and economic model.
@nl
P2093
P356
P1476
The effectiveness and cost-eff ...... tic review and economic model.
@en
P2093
M Jeffreys
R Anderson
P356
10.3310/HTA16210
P577
2012-01-01T00:00:00Z